Proteomic analysis of dog tears for potential cancer markers

Campos, Carla de Freitas; Cole, Nerida; Dyk, Derek Van; Walsh, Bradley J.; Diakos, Penelope; Almeida, Denise E. de; Torrecilhas, Adriana; Laus, José Luiz; Willcox, Mark

doi:10.1016/j.rvsc.2007.11.006

Cited by 47 publications

(58 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously, we showed different protein distributions in the tear fluid of breast cancer patients and healthy controls in a SELDI-TOF-based profiling study (17,27). Another comparative MALDI-TOF-TOF-driven analysis of healthy dog’s tear fluid and dogs diagnosed with cancer has been published (28). To our knowledge, no other comparative tear fluid proteomic studies for breast cancer have been reported.…”

Section: Introductionmentioning

confidence: 99%

Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach

et al. 2012

View full text Add to dashboard Cite

Noninvasive biomarkers are urgently needed for early detection of breast cancer since the risk of recurrence, morbidity and mortality are closely related to disease stage at the time of primary surgery. In the past decade, many proteomics-based approaches were developed that utilize the protein profiling of human body fluids or identification of putative biomarkers to obtain more knowledge on the effects of cancer emergence and progression. Herein, we report on an analysis of proteins in the tear fluid from breast carcinoma patients and healthy women using a de novo proteomic approach and 25 mixed samples from each group. This study included 25 patients with primary invasive breast carcinoma and 25 age-matched healthy controls. We performed a MALDI-TOF-TOF-driven semi-quantitative comparison of tear protein levels in cancer (CA) and control (CTRL) using a de novo approach in pooled samples. Over 150 proteins in the tear fluid of CTRL and CA were identified. Using an in-house-developed algorithm we found more than 20 proteins distinctly upregulated or downregulated in the CTRL and CA groups. We identified several proteins that had modified expression in breast cancer patients. These proteins are involved in host immune system pathways (e.g., C1Q1 or S100A8) and different metabolic cascades (ALDH3A or TPI). Further validation of the results in an independent population combined with individual protein profiling of participants is needed to confirm the specificity of our findings and may lead to a better understanding of the pathological mechanism of breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Lacryglobin shares 52% identity and 68% similarity with the breast cancer biomarker mammaglobin A [76,126]. Furthermore, we also demonstrated that a number of differences could be detected using peptide mass fingerprinting between the tears of healthy dogs and dogs with cancer from 2DGE [128]. Furthermore, we also demonstrated that a number of differences could be detected using peptide mass fingerprinting between the tears of healthy dogs and dogs with cancer from 2DGE [128].…”

Section: Systemic Diseasesmentioning

confidence: 53%

“…Additionally, its gene (mammaglobin B gene) was reported to be a potential marker for metastasis of breast cancer cells to lymph nodes [127]. Differences were found in levels of actin and albumin and in an unidentified protein, which may be analogous to human lacryglobulin [128]. Differences were found in levels of actin and albumin and in an unidentified protein, which may be analogous to human lacryglobulin [128].…”

Section: Systemic Diseasesmentioning

confidence: 99%

Tear Fluid Protein Biomarkers

You¹,

Willcox²,

Madigan³

et al. 2013

Advances in Clinical Chemistry

Self Cite

View full text Add to dashboard Cite

“…For instance, potentially relevant changes in the serum of dogs with high grade lymphomas or mammary tumours were reported (Gaines et al, 2007;Ratcliffe et al, 2009;Atherton et al, 2013;Mobasheri, 2013;Aresu et al, 2014;Zamani-Ahmadmahmudi et al, 2014). Furthermore, tear fluid analysis found changes in the amount of actin, albumin and an unidentified protein in dogs with different kinds of cancer (de Freitas Campos et al, 2008). MS-based proteome analysis has also been applied to solid tumour lysates, including canine lymphomas, MCTs and mammary tumours (McCaw et al, 2007;Klopfleisch et al, 2010b;Klose et al, 2011;Schlieben et al, 2012Schlieben et al, , 2013Gorges and Pantel, 2013).…”

Section: Personalized Medicine In Veterinary Oncology: Where Are We?mentioning

confidence: 99%

Personalised medicine in veterinary oncology: One to cure just one

Klopfleisch

2015

The Veterinary Journal

View full text Add to dashboard Cite

Proteomic analysis of dog tears for potential cancer markers

Cited by 47 publications

References 14 publications

Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach

Comparison of tear protein levels in breast cancer patients and healthy controls using a de novo proteomic approach

Tear Fluid Protein Biomarkers

Personalised medicine in veterinary oncology: One to cure just one

Contact Info

Product

Resources

About